Search Results - "De Boer, R. A."

The fibrosis marker galectin-3 and outcome in the general population by de Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L., Bakker, S. J. L., van der Harst, P.

“…  de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJL, van der Harst P (University of Groningen). The…”
Get full text

SARS-CoV-2 incidence in secondary schools; the role of national and school-initiated COVID-19 measures by Jonker, L, Linde, K J, de Boer, A R, Ding, E, Zhang, D, de Hoog, M L A, Herfst, S, Heederik, D J J, Fraaij, P L A, Bluyssen, P M, Wouters, I M, Bruijning-Verhagen, P C J L

“…Our aim was to gain insight into the effect of COVID-19 measures on SARS-CoV-2 incidence in secondary schools and the association with classroom CO…”
Get full text

Telomere length loss due to smoking and metabolic traits by Huzen, J., Wong, L. S. M., Veldhuisen, D. J., Samani, N. J., Zwinderman, A. H., Codd, V., Cawthon, R. M., Benus, G. F. J. D., Horst, I. C.C., Navis, G., Bakker, S. J. L., Gansevoort, R. T., Jong, P. E., Hillege, H. L., Gilst, W. H., Boer, R. A., Harst, P.

“…Objectives Human age‐dependent telomere attrition and telomere shortening are associated with several age‐associated diseases and poorer overall survival. The…”
Get full text

Vitamin D biology in heart failure: molecular mechanisms and systematic review by Meems, Laura M G, van der Harst, P, van Gilst, W H, de Boer, R A

“…Vitamin D has recently been suggested as an important mediator of blood pressure and cardiovascular disease, including heart failure. In patient with heart…”
Get more information

The fibrosis-cell death axis in heart failure by Piek, A., de Boer, R. A., Silljé, H. H. W.

“…Cardiac stress can induce morphological, structural and functional changes of the heart, referred to as cardiac remodeling. Myocardial infarction or sustained…”
Get full text

Hallmarks of cancer in patients with heart failure: data from BIOSTAT-CHF by van den Berg, P F, Yousif, L I, Markousis-Mavrogenis, G, Shi, C, Bracun, V, Tromp, J, de Wit, S, Appels, Y, Screever, E M, Aboumsallem, J P, Ouwerkerk, W, van Veldhuisen, D J, Silljé, H H W, Voors, A A, de Boer, R A, Meijers, Wouter C

“…Within cardio-oncology, emerging epidemiologic studies have demonstrated a bi-directional relationship between heart failure (HF) and cancer. In the current…”
Get full text

Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II‐induced hypertensive heart disease in rats by Snijder, P M, Frenay, A R, Boer, R A, Pasch, A, Hillebrands, J L, Leuvenink, H G D, Goor, H

“…Background and Purpose Hypertension is an important mediator of cardiac damage and remodelling. Hydrogen sulfide (H2S) is an endogenously produced…”
Get full text

Prognostic value of temporal patterns of left atrial reservoir strain in patients with heart failure with reduced ejection fraction by Abou Kamar, S., Aga, Y. S., de Bakker, M., van den Berg, V. J., Strachinaru, M., Bowen, D., Frowijn, R., Akkerhuis, K. M., Brugts, J. J., Manintveld, O., Umans, V., Geleijnse, M., de Boer, R. A., Boersma, E., Kardys, I., van Dalen, B. M.

“…Background We investigated whether repeatedly measured left atrial reservoir strain (LASr) in heart failure with reduced ejection fraction (HFrEF) patients…”
Get full text

Biomarkers in heart failure with preserved ejection fraction by Meijers, W. C., van der Velde, A. R., de Boer, R. A.

“…Biomarkers are widely used and studied in heart failure. Most studies have described the utility and performance of biomarkers in sub-studies of randomised…”
Get full text

Telemedicine in heart failure—more than nice to have? by Eurlings, C. G. M. J., Boyne, J. J., de Boer, R. A., Brunner-La Rocca, H. P.

“…Telemedicine in chronic diseases like heart failure is rapidly evolving and has two important goals: improving and individualising care as well as reducing…”
Get full text

Progress in heart failure management in the Netherlands and beyond: long-term commitment to deliver high-quality research and patient care by Meems, L. M. G., van Veldhuisen, D. J., de Boer, R. A.

“…Heart failure (HF) remains a major global problem. In the Netherlands, 1.5–2.0% of the total population is diagnosed with HF. Over 30,000 HF patients are…”
Get full text

Prevalence and cardiac phenotype of patients with a phospholamban mutation by Hof, I. E., van der Heijden, J. F., Kranias, E. G., Sanoudou, D., de Boer, R. A., van Tintelen, J. P., van der Zwaag, P. A., Doevendans, P. A.

“…Pathogenic mutations in the phospholamban ( PLN ) gene may give rise to inherited cardiomyopathies due to its role in calcium homeostasis. Several PLN…”
Get full text

Atrial fibrillation: trends in prevalence and antithrombotic prescriptions in the community by Joosten, L. P. T., de Boer, A. R., van Eerde, E. J. B., van Doorn, S., Hoes, A. W., Bots, M. L., Rutten, F. H., Geersing, G. J.

“…Introduction In the past decade, the atrial fibrillation (AF) landscape, including the treatment modalities, has drastically changed. This raises the question…”
Get full text

Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides by Meijers, W. C., Hoekstra, T., Jaarsma, T., van Veldhuisen, D. J., de Boer, R. A.

“…Aims Heart failure with preserved ejection fraction (HFpEF) is common and its management remains difficult. B-type natriuretic peptide (BNP) levels are used to…”
Get full text

Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST) by te Rijdt, W. P., Hoorntje, E. T., de Brouwer, R., Oomen, A., Amin, A., van der Heijden, J. F., Karper, J. C., Westenbrink, B. D., Silljé, H. H. W., te Riele, A. S. J. M., Wiesfeld, A. C. P., van Gelder, I. C., Willems, T. P., van der Zwaag, P. A., van Tintelen, J. P., Hillege, J. H., Tan, H. L., van Veldhuisen, D. J., Asselbergs, F. W., de Boer, R. A., Wilde, A. A. M., van den Berg, M. P.

“…Background The p.Arg14del (c.40_42delAGA) phospholamban (PLN) pathogenic variant is a founder mutation that causes dilated cardiomyopathy (DCM) and…”
Get full text

BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status by Jansen, M., Christiaans, I., van der Crabben, S. N., Michels, M., Huurman, R., Hoedemaekers, Y. M., Dooijes, D., Jongbloed, J. D. H., Boven, L. G., Lekanne Deprez, R. H., Wilde, A. A. M., Jans, J. J. M., van der Velden, J., de Boer, R. A., van Tintelen, J. P., Asselbergs, F. W., Baas, A. F.

“…Background Hypertrophic cardiomyopathy (HCM) is the most prevalent monogenic heart disease, commonly caused by truncating variants in the MYBPC3 gene. HCM is…”
Get full text

Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction by Nauta, J. F., Santema, B. T., van der Wal, M. H. L., Koops, A., Warink-Riemersma, J., van Dijk, K., Inkelaar, F., Prückl, S., Suwijn, J., van Deursen, V. M., Meijers, W. C., Coster, J., Westenbrink, B. D., de Boer, R. A., Hummel, Y., van Melle, J., van Veldhuisen, D. J., van der Meer, P., Voors, A. A.

“…Objective Recent studies have reported suboptimal up-titration of heart failure (HF) therapies in patients with heart failure and a reduced ejection fraction…”
Get full text

An Investigation of CYP2D6 Genotype and Response to Metoprolol CR/XL During Dose Titration in Patients With Heart Failure: A MERIT-HF Substudy by Batty, J A, Hall, A S, White, H L, Wikstrand, J, de Boer, R A, van Veldhuisen, D J, van der Harst, P, Waagstein, F, Hjalmarson, Å, Kjekshus, J, Balmforth, A J

“…To explore the pharmacogenetic effects of the cytochrome P450 (CYP)2D6 genotype in patients with systolic heart failure treated using…”
Get full text

Strength of patient cohorts and biobanks for cardiomyopathy research by de Boer, R. A., Nijenkamp, L. L. A. M., Silljé, H. H. W., Eijgenraam, T. R., Parbhudayal, R., van Driel, B., Huurman, R., Michels, M., Pei, J., Harakalova, M., van Lint, F. H. M., Jansen, M., Baas, A. F., Asselbergs, F. W., van Tintelen, J. P., Brundel, B. J. J. M., Dorsch, L. M., Schuldt, M., Kuster, D. W. D., van der Velden, J.

“…In 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and…”
Get full text

Awareness of atrial fibrogenesis and natriuretic peptide release by Meijers, W. C. F. W., Jaarsma, T., van Veldhuisen, D. J., Hoekstra, T., de Boer, R. A.

“…Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. Atrial natriuretic peptide in patients with heart failure…”
Get full text